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Abstract
Background: Although half of HIV-infected patients develop lipodystrophy and metabolic complications, there exists no
simple clinical screening tool to discern the high from the low-risk HIV-infected patient. Thus, we evaluated the associations
between waist circumference (WC) combined with triglyceride (TG) levels and the severity of lipodystrophy and
cardiovascular risk among HIV-infected men and women.
Methods: 1481 HIV-infected men and 841 HIV-infected women were recruited between 2005 and 2009 at the metabolic
clinic of the University of Modena and Reggio Emilia in Italy. Within each gender, patients were categorized into 4 groups
according to WC and TG levels. Total and regional fat and fat-free mass were assessed by duel-energy x-ray absorptiometry,
and visceral adipose tissue (VAT) and abdominal subcutaneous AT (SAT) were quantified by computed tomography. Various
cardiovascular risk factors were assessed in clinic after an overnight fast.
Results: The high TG/high WC men had the most VAT (208.0694.4 cm
2), as well as the highest prevalence of metabolic
syndrome (42.2%) and type-2 diabetes (16.2%), and the highest Framingham risk score (10.366.5) in comparison to other
groups (p,0.05 for all). High TG/high WC women also had elevated VAT (150.0697.9 cm
2) and a higher prevalence of
metabolic syndrome (53.3%), hypertension (30.5%) and type-2 diabetes (12.0%), and Framingham risk score(2.962.8) by
comparison to low TG/low WC women (p,0.05 for all).
Conclusions: A simple tool combining WC and TG levels can discriminate high- from low-risk HIV-infected patients.
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Introduction
Lipodystrophy is commonly observed among HIV-infected
patients receiving antiretroviral therapy (ART) [1]. The HIV-
lipodystropy phenotype is broadly characterized by generalized
atrophy of subcutaneous adipose tissue (SAT) and/or hypertrophy
of visceral adipose tissue (VAT) [2,3] and increased ectopic fat
storage [4,5]. Not surprisingly, the majority of lipodystrophic HIV-
infected patients exhibit the classic constellation of cardiovascular
risk factors including visceral obesity, insulin resistance, dyslipide-
mia, hypertension, endothelial dysfunction [6], and subclinical
atherosclerosis [7]. These patients are also at significantly greater
prospective risk of developing type-2 diabetes [8] or experiencing
myocardial infarction [9]. Nevertheless, only ,50% of HIV-
infected patients on ART ever develop lipodystrophy along with
the associated cardiovascular and metabolic complications [1,6].
Thus, there exists an unmet need for a simple yet accurate clinical
tool to discern the high-risk from the low-risk HIV-infected
patient.
In otherwise healthy populations, waist circumference (WC) has
been advocated as a simple tool for identifying the high-risk,
abdominally obese patient [10,11]. However, the sensitivity of WC
for identifying patients at cardiovascular risk may be limited due to
its inability to distinguish VAT from abdominal SAT. Given that
excess VAT has been shown to predict metabolic complications
[12,13], morbidity [14], and mortality [15] independent of other
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25032AT depots, including abdominal SAT, this distinction is not trivial.
Lemieux and colleagues previously suggested that an elevated
triglyceride (TG) level can be used as a marker of excess VAT
storage and associated metabolic abnormalities in individuals with
elevated WC [16]. This combination of an elevated WC and
elevated TG levels, termed the hypertriglyceridemic waist phenotype,
has since been proven a simple, but reliable screening tool for
identifying non-HIV-infected individuals with increased visceral
adiposity [17] and with elevated cardiovascular disease risk [18].
The objective of the current investigation was to evaluate the
associations between a combination of WC and TG levels with
body composition and cardiovascular risk among 2322 HIV-
infected men and women.
Methods
Subjects
The current cross-sectional investigation includes 2322 HIV-
infected patients (1481 men and 841 women) recruited at the
metabolic clinic of the University of Modena and Reggio Emilia in
Italy between 2005 and 2009. Patients from HIV clinics
throughout Italy are referred or get direct access to the
multidisciplinary treatment at the metabolic clinic where they
obtain comprehensive metabolic and anthropometric diagnostic
and therapeutic assessments for the presence of lipodystrophy and
non-infectious comorbidities.
Inclusion criteria were serologically documented HIV-1 infec-
tion, age .18 years, at least 18 months of ART exposure, and, for
patients with established diagnoses of dyslipidemia and hypergly-
cemia, stable lipid-lowering and diabetes therapy for at least 6
months. A signed informed-consent form to participate in this
study was obtained from each patient. Patients were excluded if
they reported or had documented evidence of any of the following
cardiovascular conditions: previous myocardial infarction (n=70),
stroke (n=11), percutaneous coronary angioplasty (n=57),
coronary artery bypass surgery (n=8), or peripheral vascular
disease (n=19). The study was approved by local institutional
review board (Comitato Etico Provinciale di Modena).
Demographic Outcomes
Demographic and clinical data, including duration of HIV
infection, prior diseases (Centers for Disease Control and
Prevention classification), ART history, and lifestyle were obtained
by medical chart review. Smoking was categorized into the
following categories: non-smoker, light smoker (,10 cigarettes per
day), or heavy smoker ($10 cigarettes per day). Alcohol
consumption was separated into heavy ($20 g of ethanol per
day), light (,20 g of ethanol per day), or none. Patients were
considered to be physically active if they reported $4 hrs per week
of any form of exercise.
Cardiovascular risk factors
Insulin resistance (IR) was calculated using the homeostasis
model assessment equation (HOMA-IR=[fasting insulin in mU/
mL 6 fasting glucose in mmol/L)/22.5]. Total cholesterol, low-
density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, triglyceride, apolipoprotein A and B, glucose,
and insulin levels were measured after an overnight fast. The
presence of metabolic syndrome was diagnosed according to the
clinical criteria proposed by the NCEP-Adult Treatment Panel III
(NCEP-ATP-III) [19]. Finally, the Framingham risk score for each
patient was calculated according to the equations proposed by the
ATP-III [19].
Anthropometrics
All patients underwent physical examinations at the same time
point as blood was taken. Waist, hip, and thigh circumference,
height and body weight were measured by a single operator. Waist
circumference was measured in the narrowest point at the mid-
way between the lowest rib and the iliac crest with the subject
standing at the end of expiration. Hip circumference was taken at
the largest point at the greater trochanters, while thigh
circumference was measured mid-way between the hip and knee.
The circumferences were calculated as the average of three
measurements. Body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters.
Body Composition
Whole body, trunk, leg and arm fat and lean mass were
quantified using dual-energy x-ray absorptiometry (Lunar DPX-
MD; Lunar Corporation, Madison, WI for scans before July 2007
and Hologic 4500 QDR Elite, Bedford, Massachussets for scans
after that date). A single CT image at the level of the L4 vertebra
was taken for quantification of VAT and abdominal SAT using a
64-multislice CT scanner (LightSpeed VTC; General Electric
Medical System). Each CT image was analyzed using software
application based on Advantage windows 4.4 GE medical system.
Two radiologists assessed CT images for VAT and abdominal
SAT. Agreement between the operators for VAT measurement
was calculated on a subset of 40 scans demonstrated a high
repeatability (r=0.97, ß=0.98). Similar results were observed for
abdominal SAT.
HIV History
Plasma HIV-1 RNA levels, CD4+ cell counts (most recent value
and nadir), and cumulative exposure to non-nucleoside reverse-
transcriptase inhibitors (NNRTI), nucleoside reverse-transcriptase
inhibitors (NRTIs), and PIs were recorded. HIV load was
categorized as undetectable if ,40 copies/mL were present.
Previous AIDS diagnosis was defined according to the Centers for
Disease Control and Prevention category C. Lipodystrophy was
defined using HIV Outpatient Study (HOPS) definition, with
anthropomorphic categorizations of lipoatrophy, lipohypertrophy,
and mixed form, as previously described [20].
Patient categorization
Within each gender, patients were separated into 4 distinct
groups based on their WC and TG levels: low WC/low TG, low
WC/high TG, high WC/low TG, and high WC/high TG. For
men, the cut-off values for WC and TG were $90 cm and
$2.0 mmol/L, respectively, while those for women were $85 cm
and $1.5 mmol/L, respectively. These cut-off values have
previously been shown to provide the optimal sensitivity and
specificity in identifying cardiovascular risk among men and
women [16,21].
Statistical Analysis
Differences in all variables were calculated between the four
WC and TG level groups. Differences in categorical variables were
analyzed using Chi-square test. Differences in means of continuous
variables with a normal distribution were analyzed using ANOVA,
followed by Bonferroni post-hoc testing. Where continuous data
was not normally distributed, a Kruskal-Wallis test was performed
to assess differences between group medians, followed by post-hoc
testing using the Mann-Whitney test. Age and physical activity
were included as covariates in the analyses of anthropometric,
body composition, and cardiovascular risk factors. A p value
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were performed using STATA 10.1 Intercooled version for Mac,
StataCorp, Collage Station, TX, USA.
Results
The demographic, anthropometric, body composition and
cardiovascular risk factors for the 1481 HIV-infected men and
841 women grouped according to their WC and TG levels are
presented in Tables 1 and 2, respectively. Men in the high WC
groups were approximately 3 years older than those in the low WC
groups (p,0.05). Additionally, the men with a high TG/high WC
were less active (29.0% physically active) than men in all other
groups (range: 35.5–44.5%; p,0.05). A similar pattern was
observed among the women, with the high TG/high WC group
being older (44.167.8 versus 42.365.7 years, respectively;
p,0.05) and less active than the low TG/low WC group (22.2
versus 33.5% physically active, respectively; p,0.05). No differ-
ences in smoking or alcohol consumption were observed in either
gender. Accordingly, all comparisons of anthropometric, body
composition, and cardiovascular risk outcomes statistically con-
trolled for age and physical activity level.
Table 1. Demographics, anthropometrics, body composition, and cardiovascular risk factors among 1481 HIV-infected men.
Low TG/Low WC High TG/Low WC Low TG/High WC High TG/High WC
n (%) 308 (20.8) 611 (41.3) 166 (11.2) 396 (26.7)
Demographics
Age, y, mean (SD) 44.2 (7.4)
a 44.9 (6.5)
a 47.2 (7.4)
b 48.2 (7.5)
b
Physical activity, n (%) 137 (44.5)
a 217 (35.5)
b 66 (39.8)
a, b 115 (29.0)
Smoke (.10 cigs/day), n (%) 104 (33.8)
a 211 (34.5)
a 43 (25.9)
a 119 (30.0)
a
Alcohol consumption, n (%) 148 (48.1)
a 277 (45.3)
a 91 (54.8)
a 215 (54.3)
a
Anthropometrics
BMI, kg/m
2, mean (SD) 21.9 (2.2)
a 22.2 (2.2)
a 27.1 (3.6)
b 27.4 (3.6)
b
Waist circumference, cm, mean (SD) 81.3 (5.3)
a 82.2 (4.9)
a 98.1 (8.3)
b 98.0 (8.1)
b
Hip circumference, cm, mean (SD) 87.2 (4.2)
a 86.7 (4.1)
a 95.5 (5.6)
b 95.0 (6.0)
b
Thigh circumference cm, mean (SD) 46.6 (3.9)
a 46.2 (3.7)
a 50.5 (4.0)
b 50.0 (4.1)
b
Body Composition
VAT, cm
3, mean (SD) 94.9 (60.6) 117.7 (70.3) 178.8 (78.7) 208.0 (94.4)
SAT, cm
3, mean (SD) 81.2 (58.7)
a 75.5 (54.5)
a 215.2 (114.8) 184.4 (98.7)
Total fat, kg, mean (SD) 7.6 (3.3)
a 7.4 (3.7)
a 16.4 (7.2)
b 15.6 (6.5)
b
Total lean, kg, mean (SD) 56.1 (35.2)
a, b 53.5 (6.1)
a 64.0 (49.0)
b 61.9 (26.8)
b
Arm fat, kg, mean (SD) 1.0 (0.6)
a 1.1 (0.6)
a 2.8 (1.8)
b 2.6 (1.4)
b
Arm lean, kg, mean (SD) 7.4 (1.4)
a 7.3 (1.3)
a 7.9 (1.4)
b 7.9 (1.4)
b
Leg fat, kg, mean (SD) 1.9 (1.3) 1.4 (0.9) 3.7 (2.5) 3.2 (2.1)
Leg lean, kg, mean (SD) 17.1 (2.4)
a 17.1 (2.3)
a 19.1 (3.0)
b 19.3 (2.6)
b
Cardiovascular Risk Factors
Framingham risk, mean (SD) 5.8 (4.5) 9.5 (7.2) 7.6 (5.7) 10.3 (6.5)
Diabetes, n (%) 17 (5.5)
a 43 (7.0)
a 12 (7.2)
a 64 (16.2)
Hypertension, n (%) 90 (29.2) 242 (39.6)
a 80 (48.2)
a,b 208 (52.5)
b
Metabolic syndrome (ATP-III), n (%) 11 (3.6) 195 (31.9) 18 (10.8) 190 (48.0)
Fibrate use, n (%) 9(2.9)
a 64 (10.5)
b 4 (2.4)
a 33 (8.3)
b
Statin use, n (%) 8 (2.6)
a 27 (4.4)
a 5 (3.0)
a 43 (10.9)
Triglycerides, mmol/L, mean (SD) 1.1 (0.3)
a 3.2 (2.2)
b 1.1 (0.2)
a 3.1 (1.9)
b
Total cholesterol, mmol/L, mean (SD) 4.3 (0.9)
a 5.1 (1.2)
b 4.4 (1.1)
a 5.1 (1.3)
b
HDL, mmol/L, mean (SD) 1.2 (0.4)
a 1.0 (0.4)
b 1.2 (0.4)
a 1.0 (0.3)
b
LDL, mmol/L, mean (SD) 2.7 (0.8)
a 3.0 (1.0)
b 2.7 (0.9)
a 3.0 (1.0)
b
ApoA1, mg/dL, mean (SD) 139.0 (29.0)
a 133.8 (24.7)
b 140.1 (25.6)
a,b 135.2 (24.8)
a, b
ApoB, mg/dL, mean (SD) 86.3 (22.8)
a 109.2 (28.9)
b 89.0 (24.8)
a 109.3 (26.2)
b
HOMA-IR, mean (SD) 3.6 (8.6)
a 4.2 (3.9)
a 4.2 (2.8)
a 6.2 (6.1)
Albuminuria, n (%) 22 (7.1)
a 64 (10.5)
a 13 (7.8)
a 50 (12.6)
a
Note:
Continuous variables are presented as mean (6 SD), while rates are presented as n (%). Unless otherwise denoted, all groups are significantly different from one another
(P,0.05). Groups marked by the same superscript letter are not different from one another (P.0.05).
Apo, apolipoprotein; ATP-III, adult treatment panel III; BMI, body mass index; CAC, coronary artery calcium; HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment of insulin resistance; IQR, inter quartile range; LDL, low-density lipoprotein; SD,standard deviation; VAT, visceral adipose tissue.
doi:10.1371/journal.pone.0025032.t001
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between men with the same WC category, but were significantly
greater in the high WC than in the low WC groups (Table 1). The
same was true among the women (Table 2), with the exception of a
slightly smaller thigh circumference in the high TG/low WC than
in the high TG/low WC group (42.764.0 cm and 44.06cm,
respectively; p,0.05).
In the men, VAT increased progressively from the lowest value
among thelowTG/low WC(94.9660.6 cm
2)tothehighestvalue in
the high TG/high WC group (208.0694.4 cm
2), meanwhile within
each WC category, leg fat mass was 0.5 kg lower in the high TG
versus the low TG groups (p,0.05, for all comparisons; Figure 1). In
the women, VAT was highest among the high WC groups, but not
different between the low TG/high WC and high TG/high WC
groups (139.26146.7 cm
2 and 150.0697.9 cm
2, respectively;
Figure 1). Additionally, in women with a low WC, leg fat was
0.8 kg lower in the high versus the low TG women (p,0.05). Aside
from these differences, measures of total and regional body fat and
leanmassweresimilarbetweengroupswithinthesameWCcategory
but significantly higher in the high WC versus the low WC groups.
In general, after control for age and physical activity level,
cardiovascular risk was greatest among men in the high TG/high
Table 2. Demographics, anthropometrics, body composition, and cardiovascular risk factors among 841 HIV-infected women.
Low TG/Low WC High TG/Low WC Low TG/High WC High TG/High WC
n (%) 284 (33.8) 245 (29.1) 145 (17.2) 167 (19.9)
Demographics
Age, y, mean (SD) 42.3 (5.7)
a 43.2 (6.8)
a,b 43.3 (7.5)
a,b 44.1 (7.8)
b
Physical activity, n (%) 95 (33.5)
a 65 (26.5)
a,b 37 (25.5)
a,b 37 (22.2)
b
Smoke (.10 cigs/day), n (%) 83 (29.2)
a 74 (30.2)
a 30 (20.7)
a 46 (27.5)
a
Alcohol consumption, n (%) 122 (43.0)
a 86 (35.1)
a 63 (43.5)
a 64 (38.3)
a
Anthropometrics
BMI, kg/m
2, mean (SD) 20.5 (2.1)
a 20.5 (2.0)
a 25.4 (4.1)
b 26.3 (4.2)
b
Waist circumference, cm, mean (SD) 76.4 (5.1)
a 76.8 (5.4)
a 92.6 (7.8)
b 93.7 (8.1)
b
Hip circumference, cm, mean (SD) 85.0 (4.9)
a 84.9 (4.3)
a 94.1 (6.9)
b 94.6 (8.2)
b
Thigh circumference, cm, mean (SD) 44.0 (3.9) 42.7 (4.0) 47.0 (4.9)
a 47.2 (5.8)
a
Body Composition
VAT, cm
3, mean (SD) 72.9 (39.1) 91.4 (68.0) 139.2 (146.7)
a 150.0 (97.9)
a
SAT, cm
3, mean (SD) 143.7 (84.8)
a 128.2 (63.4)
a 266.4 (122.6)
b 258.3 (111.5)
b
Total fat, kg, mean (SD) 10.8 (4.0)
a 9.9 (3.7)
a 19.2 (7.5)
b 18.9 (7.6)
b
Total lean, kg, mean (SD) 38.2 (3.9)
a 38.8 (4.2)
a 42.9 (5.1)
b 43.9 (6.3)
b
Arm fat, kg, mean (SD) 1.7 (0.8)
a 1.6 (0.7)
a 3.7 (2.1)
b 3.6 (1.9)
b
Arm lean, kg, mean (SD) 4.5 (0.7)
a 4.7 (1.5)
a 5.2 (1.0)
b 5.4 (1.0)
b
Leg fat, kg, mean (SD) 3.0 (1.8) 2.2 (1.4) 4.7 (2.7)
a 4.2 (3.0)
a
Leg lean, kg, mean (SD) 12.1 (1.6)
a 12.2 (1.8)
a 13.4 (1.9)
b 13.7 (2.0)
b
Cardiovascular Risk Factors
Framingham risk, mean (SD) 1.5 (1.3)
a 2.6 (2.6)
b 1.4 (0.9)
a 2.9 (2.8)
b
Diabetes, n (%) 11 (3.9)
a 9 (3.7)
a 8 (5.5)
a,b 20 (12.0)
b
Hypertension, n (%) 41 (14.4) 60 (24.5)
a 39 (26.9)
a 51 (30.5)
a
Metabolic syndrome (ATP-III), n (%) 6 (2.1) 62 (25.3) 20 (13.8) 93 (55.7)
Fibrate use, n (%) 6 (2.1)
a 12 (4.9)
a,b 3 (2.1)
a,b 11 (6.6)
b
Statin use, n (%) 4 (1.4)
a 5 (2.0)
a 5 (3.5)
a,b 13 (7.8)
b
Triglycerides, mmol/L, mean (SD) 1.0 (0.3)
a 2.6 (1.3)
b 1.0 (0.3)
a 2.5 (1.2)
b
Total cholesterol, mmol/L, mean (SD) 4.6 (1.2)
a 5.1 (1.2)
b 4.8 (1.1)
a,b 5.4 (1.3)
HDL, mmol/L, mean (SD) 1.5 (0.5)
a 1.2 (0.4)
b 1.5 (0.4)
a 1.2 (0.3)
b
LDL, mmol/L, mean (SD) 2.7 (0.9)
a 3.1 (1.0)
b,c 2.9 (0.9)
a,b 3.3 (1.1)
c
ApoA1, mg/dL, mean (SD) 159.6 (33.0)
a,b 147.7 (29.4)
c 160.8 (30.4)
a 150.3 (29.1)
b,c
ApoB, mg/dL, mean (SD) 85.0 (24.2)
a 107.7 (29.3)
b 91.2 (23.7)
a 112.8 (29.6)
b
HOMA-IR, mean (SD) 3.0 (3.1)
a 3.9 (3.4)
b 4.0 (3.4)
a,b 5.2 (5.9)
b
Albuminuria, n (%) 16 (5.6)
a 20 (8.2)
a 11 (7.6)
a 9 (5.4)
a
Note:
Continuous variables are presented as mean (6 SD), while rates are presented as n (%). Unless otherwise denoted, all groups are significantly different from one another
(P,0.05). Groups marked by the same super-script letter are not different from one another (P.0.05).
Apo, apolipoprotein; ATP-III, adult treatment panel III; BMI, body mass index; CAC, coronary artery calcium; HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment of insulin resistance; IQR, inter quartile range; LDL, low-density lipoprotein; SD,standard deviation; VAT, visceral adipose tissue.
doi:10.1371/journal.pone.0025032.t002
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prevalence of metabolic syndrome was significantly higher in the
high TG/high WC men than in any other group (48.0% vs. range
of 3.6–31.9%; p,0.05 for all comparisons). Additionally, the
prevalence of type-2 diabetes was highest in the high TG/high
WC group compared to all groups (16.2% versus 5.5–7.2%;
p,0.05 for all comparisons) (Figure 3). Mean Framingham risk
score was also significantly higher in the high TG/high WC men
in comparison to all other groups (10.366.5 versus 5.8 to 9.5,
respectively; p,0.05 for all comparisons; Table 1).
Globally, differences in the cardiovascular risk profile in the
HIV-infected women according to WC and TG categories were
less substantial than those observed in men (Table 2). Nevertheless,
the prevalence of metabolic syndrome was significantly higher in
the high TG/high WC women than in any other group (55.7% vs.
range of 2.1 to 25.8%; p,0.05 for all comparisons). Additionally,
after control for age and physical activity, high TG/high WC
women were consistently at greater cardiovascular risk than low
TG/low WC women. For example, diabetes rates in the high TG/
high WC women (12.0%) were greater than the two low WC
groups (3.7–3.9%; p,0.05). Mean Framingham risk scores were
also significantly higher in the high TG/high WC than in the low
TG/low WC women (2.962.8 vs. 1.561.3, respectively; p,0.05)
as was the prevalence of hypertension (30.5 vs. 14.4%,
respectively; p,0.05). Significant differences in cardiovascular
risk between the high TG/high WC women and the two
intermediate groups (high TG/low WC and low TG/high WC)
were less consistent.
Outcomes pertaining to the history of HIV infection and
treatment for the men and women are presented in Tables 3 and
4. Duration of exposure to any of the treatments did not differ
between any of the groups within each gender. The nadir and the
current CD4+ count were also comparable across the groups. Both
men and women with a high TG/high WC were most likely to
have a mixed form of lipodystrophy, marked by a combination of
lipohypertrophy along with lipoatrophy (57.6% and 63.5%,
respectively). Lastly, HIV-infected patients with low WC were
more likely to experience lipoatrophy, while patients with a high
WC were more likely to experience lipohypertrophy.
Discussion
In the current study of 2322 HIV-infected patients, the
combination of WC and TG levels was shown to discriminate
high-risk from low-risk HIV-infected men and women. For
instance, HIV-infected men with both high WC and high TG
Figure 1. VAT and leg fat among HIV-infected men (top panel)
and women (bottom panel) according to WC and TG category.
Bars represent means, and the error bars represent the standard
deviation. Bars with the same inset letter are not statistically different
from one another (p.0.05). All other comparisons are significant
(p,0.05).
doi:10.1371/journal.pone.0025032.g001
Figure 2. Metabolic syndrome prevalence among HIV-infected
men (top panel) and women (bottom panel) according to WC
and TG category. Bars represent prevalence (%).Bars with the same
inset letter are not statistically different from one another (p.0.05). All
other comparisons are significant (p,0.05).
doi:10.1371/journal.pone.0025032.g002
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characterized by high levels of VAT combined with relatively
low levels of thigh fat. Additionally, these men presented with
greater deteriorations in cardiovascular health, experiencing the
highest prevalence of metabolic syndrome, diabetes, hypertension,
along with insulin resistance, dyslipidemia, and elevated Framing-
ham scores. Furthermore, women with a high TG and high WC
had more VAT and a deteriorated cardiovascular profile in
contrast to low TG/low WC women. On the other hand, HIV-
infected men and women with a low WC and low TG levels
appeared to be largely protected from both these body
composition and cardiovascular consequences. Thus, the present
findings suggest a utility of WC combined with TG levels as a
simple clinical tool for discerning the severity of lipodystrophy and
associated cardiovascular risk among HIV-infected men and
women.
During the late 1990’s attention was first drawn to the potential
impact of ART on body composition when reports documented
the development of dorsocervical AT hypertrophy among HIV-
infected patients; a finding reminiscent of the classic buffalo hump of
Cushing’s syndrome [22]. The tendency for generalized fat
wasting [23], and/or excess VAT accumulation [2,3] among
HIV patients was also noted, and considered to be largely
attributable to protease inhibitor treatment. It is now established
that HIV-infected patients, particularly those treated with any
ART, commonly develop lipodystropy, characterized by general-
ized atrophy of SAT, and/or hypertrophy of VAT [6], along with
increased ectopic fat storage in non-AT tissues [4,5]. In this
regard, it is interesting that in our study the combination of two
routinely obtained clinical measures, namely WC and TG, clearly
identified HIV-patients with the most deleterious combination of
body composition changes. Specifically, the men in the current
study who met the criteria of the hypertriglyceridemic waist
phenotype had the most VAT. Conversely, the same patients also
had less abdominal SAT and thigh fat in comparison to their BMI-
and WC-matched but low-TG counterparts. Thus, as depicted in
Tables 3 and 4, both HIV-infected men and women with a high
TG/high WC were most likely to have a mixed form of
lipodystrophy (57.6% and 63.5%, respectively), marked by a
combination of lipohypertrophy and lipoatrophy.
Along with the detrimental body composition changes, many
lipodystrophic HIV-infected patients develop insulin resistance,
dyslipidemia, hypertension, endothelial dysfunction [6], type-2
diabetes [8] and cardiovascular disease [9]. Nevertheless, there
exists marked heterogeneity in cardiovascular risk among HIV-
infected patients, as only 1 in 2 HIV-infected patients on ART
ever develop these body composition and cardiovascular and
metabolic complications [1,6]. Thus, the identification and
treatment prioritization of HIV-infected individuals at highest
cardiovascular risk remains an ongoing challenge in the field. The
results of the current study indicate that the combined use of WC
and TG levels may be useful in this regard. Indeed, HIV-infected
men and women with the hypertriglyceridemic waist phenotype
were distinct from their low-risk HIV-infected counterparts, not
only in terms of body composition, but also cardiovascular risk.
Specifically, men with a high WC and high TG levels exhibited
the highest rates of diabetes, hypertension, metabolic syndrome,
along with the highest Framingham risk scores, as well as the most
pronounced insulin resistance. Women with a high TG and high
WC had the highest prevalence of metabolic syndrome, the
highest total cholesterol levels, and were consistently at greater
cardiovascular risk in comparison to the low TG/low WC groups.
The concept of the hypertriglyceridemic waist phenotype was
first suggested over a decade ago, when it was observed that an
elevated TG level can be used as a marker of excess VAT storage
and associated metabolic abnormalities in otherwise healthy
patients with elevated WC [16]. Subsequently, this phenotype
has been proven a simple, but reliable screening tool for
identifying non-HIV patients with increased visceral adiposity
[17] and elevated cardiovascular disease risk [18]. The findings of
the current study extend the utility of the hypertriglyceridemic
waist phenotype beyond the general population to the identifica-
tion of cardiovascular risk among ART-treated HIV-infected
patients, particularly men.
Due to the cross-sectional design of the current investigation we
were unable to test the utility of the hypertriglyceridemic waist
phenotype in the prediction of prospective disease risk among
HIV-infected patients; a potential focus of future research. Since
patients in this study were specifically referred to the metabolic
clinic from HIV clinics throughout Italy, it is possible that their
disease severity was greater in comparison to the overall
population of HIV patients. Thus, our findings may not be
generalizable to all HIV patients. Another limitation of this study
was the application of WC and TG thresholds which were
established in an otherwise healthy population [16]. On the other
Figure 3. Type-2 diabetes prevalence among HIV-infected men
(top panel) and women (bottom panel) according to WC and
TG category. Bars represent prevalence (%).Bars with the same inset
letter are not statistically different from one another (p.0.05). All other
comparisons are significant (p,0.05).
doi:10.1371/journal.pone.0025032.g003
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Low TG/Low WC High TG/Low WC Low TG/High WC High TG/High WC
n (%) 308 (20.8) 611 (41.3) 166 (11.2) 396 (26.7)
Risk group
IDU n (%) 109 (35.4)
a,b 206 (33.7)
a,b 62 (37.4)
a 114 (28.8)
b
MSM/Bisexual n (%) 135 (43.8)
a 251 (41.1)
a 49 (29.5)
b 138 (34.9)
b
Heterosexual n (%) 64 (20.8)
a 154 (25.2)
a 55 (33.1)
b 144 (36.4)
b
CD4+ Nadir median (IQR) 180.5 (67; 280)
a 158 (59; 270)
a 193.5 (97; 295.5)
a 170.5 (64; 266)
a
CD4+ Current median (IQR) 500 (371; 682)
a 519.5 (364; 700)
a 498 (379; 660)
a 540 (374; 737)
a
HIV Log10 VL mean (SD) 1.7 (1.7; 2.4)
a 1.69 (1.7; 2.1)
a 1.69 (1.7; 1.7)
a 1.69 (1.7; 2.3)
a
VL undetectable n (%) 177 (57.5)
a 349 (57.1)
a 106 (63.9)
a 231 (58.3)
a
Months of PI exposure median (IQR) 23 (0; 61)
a 36 (10; 68)
a 32 (1; 61)
a 36 (8; 69)
a
Months of NNRTI exposure median (IQR) 13.5 (0; 44)
a 20 (0; 49)
a 18 (0; 44)
a 16 (0; 46.5)
a
Months of NRTI exposure median (IQR) 94 (39; 131.5)
a 106 (57; 136)
a 88.5 (42; 122)
a 102 (56.5; 135)
a
Use of thymidine analogues n (%) 152 (49.4)
a 280 (45.8)
a 73 (44.0)
a 167 (42.2)
a
Use of ritonavir-boosed PIs n (%) 74 (24.0)
a 165 (27.0)
a 46 (27.7)
a 122 (30.8)
a
Lipodystrophy
Lipoatrophy n (%) 169 (54.9)
a 356 (58.3)
a 19 (11.5) 27 (6.8)
Lipohypertrophy n (%) 6 (2.0)
a 6 (1.0)
a 38 (22.9)
b 68 (17.2)
b
Mixed form n (%) 42 (13.6) 133 (21.8) 63 (38.0%) 228 (57.6%)
Note: Unless otherwise denoted, all groups are significantly different from one another (P,0.05). Groups marked by the same superscript letter are not different from
one another (P.0.05).
IDU, injection drug user; IQR, inter quartile range; HIV, human immunodeficiency virus; MSM, men who have sex with men; NNRTI, non-nucleoside reverse-transcriptase
inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; SD,standard deviation; VL, HIV RNA viral load.
doi:10.1371/journal.pone.0025032.t003
Table 4. HIV history among 841 HIV-infected women.
Low TG/Low WC High TG/Low WC Low TG/High WC High TG/High WC
n (%) 284 (33.8) 245 (29.1) 145 (17.2) 167 (19.9)
Risk group
IDU n (%) 92 (32.4)
a 80 (32.7)
a 37 (25.5)
a,b 37 (22.2)
b
Heterosexual n (%) 192 (67.6) 165 (67.4) 108 (74.5) 130 (77.8)
CD4+ Nadir median (IQR) 182 (80; 252)
a 149.5 (52; 242)
a 174 (77; 282)
a 180.5 (61; 243)
a
CD4+ Current median (IQR) 494.5 (369; 654)
a 528 (366; 712)
a 477.5 (359.5; 637.5)
a 545 (375; 742)
a
HIV Log10 VL mean (SD) 1.7 (1.7; 2.0)
a 1.7 (1.7; 2.3)
a 1.7 (1.7; 2.6)
a 1.7 (1.7; 2.0)
a
VL undetectable n (%) 186 (65.5%)
a 143 (58.4%)
a 84 (57.9%)
a 98 (58.7%)
a
Months of PI exposure median (IQR) 26.5 (0; 60)
a 34 (4; 74)
a 28 (0; 53)
a 44 (15; 76)
a
Months of NNRTI exposure median (IQR) 20 (0; 47)
a 15 (0; 41)
a 14 (0; 58)
a 16 (0; 42)
a
Months of NRTI exposure median (IQR) 106 (60.5; 137)
a 112 (78; 148)
a 102 (47; 138)
a 106 (64; 144)
a
Use of thymidine analogues n (%) 134 (47.2)
a,b 132 (53.9)
a 62 (42.8)
b 82 (49.1)
a,b
Use of ritonavir-boosed PIs n (%) 61 (21.5)
a 64 (26.1)
a 27 (18.6)
a 41 (24.6)
a
Lipodystrophy
Lipoatrophy n (%) 114 (40.1)
a 108 (44.1)
a 9( 6 . 2 )
b 3 (1.8)
b
Lipohypertrophy n (%) 11 (3.9)
a 5 (2.0)
a 35 (24.1)
b 33 (19.8)
b
Mixed form n (%) 75 (26.4) 94 (38.4) 70 (48.3) 106 (63.5)
Note:
Unless otherwise denoted, all groups are significantly different from one another (P,0.05). Groups marked by the same superscript letter are not different from one
another (P.0.05).
IDU, injection drug user; IQR, inter quartile range; HIV, human immunodeficiency virus; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-
transcriptase inhibitor; PI, protease inhibitor; SD,standard deviation; VL, HIV RNA viral load.
doi:10.1371/journal.pone.0025032.t004
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which permitted the separate analysis of HIV-infected men and
women. Further, homogeneity among the groups in demographic
factors and HIV history provides added confidence in the results
reported not being influenced by potential confounders.
In conclusion, the current study observed that the combination
of WC and TG levels can clearly and consistently discriminate the
high-risk from the low-risk HIV-infected patient. Indeed, HIV-
infected men and women meeting criteria for the hypertriglycer-
idemic waist phenotype exhibited a more deleterious form of
lipodystrophy and had elevated levels of cardiovascular risk factors
in contrast to their low-risk counterparts. These findings suggest
that a WC $90 cm and TG $2.0 mmol/L among HIV-infected
men and a WC $85 cm and TG $1.5 mmol/L among HIV-
infected women discriminates the high-risk from the low-risk
patient in terms of body composition as well as cardiovascular risk.
Acknowledgments
We thank Dr. Bruno Guidetti for database management and query con-
struction. We thank Drs Giulia Nardini and Barbara Beghetto for their
support during the organization and conduct of the trial.
Author Contributions
Conceived and designed the experiments: RR J-PD SZ GG. Performed the
experiments: GO FC PB MM SZ GG. Analyzed the data: PMJ SZ. Wrote
the paper: PMJ RR J-PD SZ IL GG.
References
1. Miller J, Carr A, Emery S, Law M, Mallal S, et al. (2003) HIV lipodystrophy:
prevalence, severity and correlates of risk in Australia. HIV Med 4: 293–301.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, et al. (1998) Visceral
abdominal-fat accumulation associated with use of indinavir. Lancet 351:
871–875.
3. Joy T, Keogh HM, Hadigan C, Dolan SE, Fitch K, et al. (2008) Relation of
body composition to body mass index in HIV-infected patients with metabolic
abnormalities. J Acquir Immune Defic Syndr 47: 174–184.
4. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S,
et al. (2002) Increased fat accumulation in the liver in HIV-infected patients with
antiretroviral therapy-associated lipodystrophy. Aids 16: 2183–2193.
5. Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, et al. (2002)
Altered myocellular and abdominal fat partitioning predict disturbance in insulin
action in HIV protease inhibitor-related lipodystrophy. Diabetes 51: 3163–3169.
6. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in
HIV-infected adults. N Engl J Med 352: 48–62.
7. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, et al. (2010)
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical
atherosclerosis in human immunodeficiency virus infected subjects. Atheroscle-
rosis 208: 222–227.
8. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. (2005) Antiretroviral
therapy and the prevalence and incidence of diabetes mellitus in the multicenter
AIDS cohort study. Arch Intern Med 165: 1179–1184.
9. Triant VA, Lee H, Hadigan C, Grinspoon SK (2007) Increased acute
myocardial infarction rates and cardiovascular risk factors among patients with
human immunodeficiency virus disease. J Clin Endocrinol Metab 92:
2506–2512.
10. Janiszewski PM, Janssen I, Ross R (2007) Does waist circumference predict
diabetes and cardiovascular disease beyond commonly evaluated cardiometa-
bolic risk factors? Diabetes Care 30: 3105–3109.
11. Janssen I, Katzmarzyk PT, Ross R (2004) Waist circumference and not body
mass index explains obesity-related health risk. Am J Clin Nutr 79: 379–384.
12. Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud’Homme D, et al. (1992)
Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and
lipoprotein levels. Diabetes 41: 826–834.
13. Janiszewski PM, Kuk JL, Ross R (2008) Is the reduction of lower-body
subcutaneous adipose tissue associated with elevations in risk factors for diabetes
and cardiovascular disease? Diabetologia 51: 1475–1482.
14. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, et al. (1999)
Visceral adiposity and incident coronary heart disease in Japanese-American
men. The 10-year follow-up results of the Seattle Japanese-American
Community Diabetes Study. Diabetes Care 22: 1808–1812.
15. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, et al. (2006)
Visceral Fat Is an Independent Predictor of All-cause Mortality in Men. Obes
Res 14: 336–341.
16. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, et al. (2000)
Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad
(hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
Circulation 102: 179–184.
17. Sam S, Haffner S, Davidson MH, D’Agostino RB, Sr, Feinstein S, et al. (2009)
Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects
with type 2 diabetes. Diabetes Care 32: 1916–1920.
18. Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Kastelein JJ, et al. (2010)
The hypertriglyceridemic-waist phenotype and the risk of coronary artery
disease: results from the EPIC-Norfolk prospective population study. Cmaj 182:
1427–1432.
19. Expert Panel on Detection E, And Treatment of High Blood Cholesterol In
Adults (2001) Executive Summary of The Third Report of The National
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel
III). Jama 285: 2486–2497.
20. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, et al. (2001)
Clinical assessment of HIV-associated lipodystrophy in an ambulatory
population. Aids 15: 1389–1398.
21. Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, et al. (2008) Type 2
diabetes without the atherogenic metabolic triad does not predict angiograph-
ically assessed coronary artery disease in women. Diabetes Care 31: 170–172.
22. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M (1998) ‘‘Buffalo hump’’
in men with HIV-1 infection. Lancet 351: 867–870.
23. Carr A, Samaras K, Burton S, Law M, Freund J, et al. (1998) A syndrome of
peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients
receiving HIV protease inhibitors. Aids 12: F51–58.
Hypertriglyceridemia, Abdominal Obesity and HIV
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25032